98 related articles for article (PubMed ID: 17495964)
1. Epigenetic control of MAGE gene expression by the KIT tyrosine kinase.
Yang B; Wu J; Maddodi N; Ma Y; Setaluri V; Longley BJ
J Invest Dermatol; 2007 Sep; 127(9):2123-8. PubMed ID: 17495964
[TBL] [Abstract][Full Text] [Related]
2. Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.
Xie C; Subhash VV; Datta A; Liem N; Tan SH; Yeo MS; Tan WL; Koh V; Yan FL; Wong FY; Wong WK; So J; Tan IB; Padmanabhan N; Yap CT; Tan P; Goh LK; Yong WP
Cell Oncol (Dordr); 2016 Apr; 39(2):175-86. PubMed ID: 26868260
[TBL] [Abstract][Full Text] [Related]
3. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia.
Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; San Jose-Eneriz E; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
Haematologica; 2007 Feb; 92(2):153-62. PubMed ID: 17296563
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia.
Zhu X; Asa SL; Ezzat S
Clin Cancer Res; 2008 Apr; 14(7):1984-96. PubMed ID: 18381936
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
8. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer.
Kondo T; Zhu X; Asa SL; Ezzat S
Clin Cancer Res; 2007 Aug; 13(16):4713-20. PubMed ID: 17699848
[TBL] [Abstract][Full Text] [Related]
9. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
10. Methylated CpG points identified within MAGE-1 promoter are involved in gene repression.
Serrano A; García A; Abril E; Garrido F; Ruiz-Cabello F
Int J Cancer; 1996 Nov; 68(4):464-70. PubMed ID: 8945617
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
12. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo.
Yang B; O'Herrin S; Wu J; Reagan-Shaw S; Ma Y; Nihal M; Longley BJ
J Invest Dermatol; 2007 Feb; 127(2):267-75. PubMed ID: 16960553
[TBL] [Abstract][Full Text] [Related]
13. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S
Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656
[TBL] [Abstract][Full Text] [Related]
15. KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas.
Blom T; Fox H; Angers-Loustau A; Peltonen K; Kerosuo L; Wartiovaara K; Linja M; Jänne OA; Kovanen P; Haapasalo H; Nupponen NN
Int J Cancer; 2008 Aug; 123(4):793-800. PubMed ID: 18506689
[TBL] [Abstract][Full Text] [Related]
16. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.
Shibuta T; Honda E; Shiotsu H; Tanaka Y; Vellasamy S; Shiratsuchi M; Umemura T
Leuk Res; 2013 Oct; 37(10):1278-86. PubMed ID: 23953880
[TBL] [Abstract][Full Text] [Related]
17. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells.
De Smet C; Loriot A; Boon T
Mol Cell Biol; 2004 Jun; 24(11):4781-90. PubMed ID: 15143172
[TBL] [Abstract][Full Text] [Related]
18. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.
Juurikivi A; Sandler C; Lindstedt KA; Kovanen PT; Juutilainen T; Leskinen MJ; Mäki T; Eklund KK
Ann Rheum Dis; 2005 Aug; 64(8):1126-31. PubMed ID: 16014680
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.
Schwarzenbach H; Eichelser C; Steinbach B; Tadewaldt J; Pantel K; Lobanenkov V; Loukinov D
BMC Cancer; 2014 Nov; 14():796. PubMed ID: 25363021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
